Sorted By Test Name - Mayo Medical Laboratories

FQUET
91727
QUIN
8302
REPII
82782
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by McPherson RA, Pincus MR. WB Saunders, Publ, New York,
Chapter 53, Part VI, pp. 961-971, 2007
Quetiapine (Seroquel)
Reference Values:
Reporting Limit: 10 ng/mL
Therapeutic and toxic ranges have not been established.
Expected steady-state Quetiapine plasma levels in patients
Receiving recommended daily dosages: 100-1000 ng/mL.
Test Performed By: Medtox Laboratories
402 W. County Road D
St. Paul, MN 55112
Quinidine, Serum
Clinical Information: Quinidine is indicated for atrial fibrillation and flutter, and life-threatening
ventricular arrhythmia. Optimal serum concentrations are in the range of 2.0 to 5.0 mcg/mL, with toxicity
apparent at levels > or =6.0 mcg/mL. Symptoms of toxicity (cinchonism) include tinnitus,
light-headedness, premature ventricular contractions, and atrioventricular block. Gastrointestinal distress
is a frequent side effect, which becomes more severe and is associated with nausea and vomiting at higher
drug concentrations. The half life of quinidine is 6 to 8 hours, and the drug lacks any significant active
metabolites. Physiologic processes that generally reduce hepatic metabolism and renal clearance increase
serum quinidine levels, while comedication with cytochrome p450 (CYP) enzyme inducers enhances
clearance and results in lower blood concentrations.
Useful For: Assessing and adjusting dosage for optimal therapeutic level Assessing toxicity
Interpretation: Optimal response to quinidine occurs when the serum level is between 2.0 to 5.0
mcg/mL.
Reference Values:
Therapeutic concentration: 2.0-5.0 mcg/mL
Toxic concentration: > or =6.0 mcg/mL
Clinical References: 1. Valdes R Jr, Jortani SA, Gheorghiade M: Standards of laboratory practice:
cardiac drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44(5):1096-1109
2. Qunidine. In Physician's Desk Reference (online) Accessed November, 2009
Rabbit Epithelium, IgE
Clinical Information: Clinical manifestations of immediate hypersensitivity (allergic) diseases are
caused by the release of proinflammatory mediators (histamine, leukotrienes, and prostaglandins) from
immunoglobulin E (IgE)-sensitized effector cells (mast cells and basophils) when cell-bound IgE
antibodies interact with allergen. In vitro serum testing for IgE antibodies provides an indication of the
immune response to allergen(s) that may be associated with allergic disease. The allergens chosen for
testing often depend upon the age of the patient, history of allergen exposure, season of the year, and
clinical manifestations. In individuals predisposed to develop allergic disease(s), the sequence of
sensitization and clinical manifestations proceed as follows: eczema and respiratory disease (rhinitis and
bronchospasm) in infants and children less than 5 years due to food sensitivity (milk, egg, soy, and wheat
proteins) followed by respiratory disease (rhinitis and asthma) in older children and adults due to
sensitivity to inhalant allergens (dust mite, mold, and pollen inhalants).
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1520